Medicare expands home infusion coverage for chronic patients
H.R. 4993 — Joe Fiandra Access to Home Infusion Act of 2025 · Filed by Brian Fitzpatrick (R-PA) · 6 cosponsors · Introduced Aug 19, 2025 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands Medicare coverage to include external infusion pumps and certain home-administered drugs that require professional supervision, starting one year after enactment. Patients with conditions requiring frequent IV or subcutaneous infusions (at least 12 times per year) can now receive these treatments at home under a qualified supplier's supervision, and Medicare must notify patients of their cost-sharing obligations compared to other care settings.
Why we flagged it
The bill's operative mechanism is a straightforward expansion of Medicare's covered services — it removes a regulatory barrier to home infusion therapy for a defined population (patients requiring frequent professional-supervised infusions) and mandates cost-sharing disclosure. This is a coverage policy change, not a tax provision, subsidy, or deregulation.
What the text implies
- The one-year implementation delay may create a gap during which beneficiaries cannot access home infusion under this new pathway, potentially affecting treatment decisions and care planning.
- The bill does not specify reimbursement rates for qualified home infusion therapy suppliers, leaving rate-setting to CMS — suppliers' financial viability depends on regulatory follow-through.
The full analysis lists 4 implications of this text.
Who stands to gain
home infusion therapy suppliers; durable medical equipment (DME) companies manufacturing external infusion pumps; specialty pharmaceutical distributors